Diagnamed Holdings (XCNQ:DMED) Change In Receivables : C$0.04 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Diagnamed Holdings Change In Receivables?

Diagnamed Holdings's change in receivables for the quarter that ended in Dec. 2024 was C$-0.01 Mil. It means Diagnamed Holdings's Accounts Receivable increased by C$0.01 Mil from Sep. 2024 to Dec. 2024 .

Diagnamed Holdings's change in receivables for the fiscal year that ended in Sep. 2024 was C$0.02 Mil. It means Diagnamed Holdings's Accounts Receivable declined by C$0.02 Mil from Sep. 2023 to Sep. 2024 .

Diagnamed Holdings's Accounts Receivable for the quarter that ended in Dec. 2024 was C$0.05 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Diagnamed Holdings's liquidation value for the three months ended in Dec. 2024 was C$-0.31 Mil.

Diagnamed Holdings Change In Receivables Historical Data

The historical data trend for Diagnamed Holdings's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnamed Holdings Change In Receivables Chart

Diagnamed Holdings Annual Data

Trend

Sep21

Sep22

Sep23

Sep24

Change In Receivables

-0.03

-0.01

0.02

Diagnamed Holdings Quarterly Data
	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial									-0.03	0.07	-0.01	-	-0.01

Diagnamed Holdings Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.04 Mil.

Diagnamed Holdings (XCNQ:DMED) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Diagnamed Holdings's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.046	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Diagnamed Holdings's accounts receivable are only considered to be worth 75% of book value:

Diagnamed Holdings's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.114	-	0.457	+	0.75 * 0.046	+	0.5 * 0
=	-0.31

Diagnamed Holdings Change In Receivables Related Terms

Thank you for viewing the detailed overview of Diagnamed Holdings's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Diagnamed Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnamed Holdings Corp (XCNQ:DMED) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

DGNMF:USA

Address

82 Richmond Street East, Toronto, ON, CAN, M5C 1P1

Website

https://www.diagnamed.com

Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.

Executives

Fabio Chianelli

Director, Senior Officer

Diagnamed Holdings Headlines

No Headlines